Carlyle to sell up to 10% stake in Piramal Pharma, Moneycontrol reports
03/07/2025 12:26
July 3 (Reuters) - U.S. private equity firm Carlyle Group CG.O is preparing to offload up to a 10% stake in India's Piramal Pharma PIRM.NS through block trades, online news portal Moneycontrol reported on Thursday, citing sources. The U.S.-based private equity firm could earn in the range of 26 billion rupees ($304.8 million) to 27 billion rupees from the sale, the report added. ($1 = 85.3090 Indian rupees) (Reporting by Hritam Mukherjee in Bengaluru; Editing by Nivedita Bhattacharjee) ((Hritam.Mukherjee@thomsonreuters.com; X: @MukherjeeHritam;))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma Receives Permanent Revocation Of Closure Order For Dahej Site
Brief: Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development
Brief: Piramal Pharma Announces Successful Closure Of Us FDA Inspection At Digwal Facility
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says
Brief: Piramal Pharma Says Closure Of US FDA Inspection At Manufacturing Facility At Lexington